Acacia Subsidiary Acquires 7 Medtech Patent Portfolios with over 150 Patents and Pending Applications
Acacia Research Corporation (Nasdaq: ACTG) announced today that a subsidiary has acquired 7 medtech patent portfolios comprised of over 150 patents and pending applications relating to medical devices, biologics and diagnostic techniques.
“Acacia continues to increase the number of patent portfolios we control in the medical technology and life sciences sector,” states Paul Ryan, CEO and President. “We are rapidly expanding our presence as a leader in patent licensing in the medical device, diagnostics and life sciences sectors.”
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.